Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Change in Cash (2016 - 2025)

Historic Change in Cash for Mimedx (MDXG) over the last 16 years, with Q3 2025 value amounting to $23.2 million.

  • Mimedx's Change in Cash rose 1745.6% to $23.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.3 million, marking a year-over-year increase of 59768.23%. This contributed to the annual value of $22.4 million for FY2024, which is 3966.36% up from last year.
  • Per Mimedx's latest filing, its Change in Cash stood at $23.2 million for Q3 2025, which was up 1745.6% from $12.4 million recorded in Q2 2025.
  • Over the past 5 years, Mimedx's Change in Cash peaked at $23.2 million during Q3 2025, and registered a low of -$33.5 million during Q1 2024.
  • Moreover, its 5-year median value for Change in Cash was $836000.0 (2023), whereas its average is $2.4 million.
  • Its Change in Cash has fluctuated over the past 5 years, first tumbled by 131609.2% in 2022, then surged by 176782.3% in 2024.
  • Mimedx's Change in Cash (Quarter) stood at -$3.5 million in 2021, then tumbled by 106.21% to -$7.3 million in 2022, then skyrocketed by 111.5% to $836000.0 in 2023, then soared by 1767.82% to $15.6 million in 2024, then surged by 48.66% to $23.2 million in 2025.
  • Its Change in Cash stands at $23.2 million for Q3 2025, versus $12.4 million for Q2 2025 and $2.0 million for Q1 2025.